Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus News 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. If you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics. That typically means negative earnings (they aren’t yet profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. While headlines focus on Tesla's car sales, tech analyst Jeff Brown says the real story is Tesla's role in a $25 trillion AI revolution — one that Nvidia's CEO himself has called a "multi-trillion-dollar future industry" — and he's uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough. Click here now to see the full report Even when a product advances through trials, profitability can still be years away. Only after reaching important milestones do companies usually attract the analyst coverage that draws institutional investment. That said, getting in on the right medical stock early can produce windfall returns. A single successful program can deliver 3x, 5x, or even 10x gains, while many other bets may never pan out. This is why some investors who follow penny stocks spread a lump sum across many biotech names; if it’s a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many small biotechs, Mainz Biomed already offers a commercial product: ColoAlert, the first DNA-based screening test for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital-health pioneers. With more than 60,000 new colorectal cancer cases in Germany each year, the market opportunity is meaningful. The company is also developing a non-invasive, blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. Still, that program is years from commercial approval. The risks remain substantial. ColoAlert is not yet available in the United States, and despite initial sales in Europe and plans to expand into South America, revenue is minimal. That limited revenue is why the company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf offering. For now, that capital is helping keep the MYNZ stock price above $1 and avoid a delisting notice. Mainz Biomed is racing to generate meaningful revenue. If it succeeds, even a relatively small investment could produce a sizable return, but the path is uncertain and prolonged. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive approach to antiviral treatment, but it also carries the financial risks that speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to advance its programs. The company reported limited cash on hand in recent filings, and investors should expect the possibility of future dilution. Still, if even one candidate successfully advances into clinical development, the valuation upside could be substantial. For investors with patience and a very high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space, but it is far from a sure thing.
| 
